Department of Urology and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
BJU Int. 2010 Jul;106(1):56-61. doi: 10.1111/j.1464-410X.2009.09095.x. Epub 2009 Dec 11.
Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder.
We retrospectively reviewed the records of patients treated with RC and orthotopic urinary diversion between January 1980 and July 2004.
In all, 260 patients underwent RC with a Studer or Hautmann orthotopic urinary diversion; the median (range) follow-up was 5.1 (0-15.6) years. Six patients (2.3%) developed local recurrence of urothelial cancer (UC) within the urethra after this treatment. The median (range) time to presentation with recurrence after RC was 2.4 (0.7-3.6) years for pT1-4 UC. Recurrences were treated with various methods, including transurethral resection, urethrectomy with conversion of neobladder to continent catheterizable diversion, and chemotherapy. At the last follow-up, four of these six patients were alive without disease, one was alive with disease, and one had died from disease.
In our experience, local recurrences involving the urethra are infrequent. Complete surgical excision can provide a good outcome. Neoadjuvant chemotherapy should be considered for recurrences with adverse clinicopathological features.
治疗(病例系列)证据水平 4
评估我们在根治性膀胱切除术(RC)和原位新膀胱尿流改道术治疗膀胱癌患者中治疗尿道复发的经验。
我们回顾性地分析了 1980 年 1 月至 2004 年 7 月期间接受 RC 和原位尿流改道术治疗的患者的记录。
共有 260 例患者接受了 Studer 或 Hautmann 原位新膀胱尿流改道术的 RC;中位(范围)随访时间为 5.1(0-15.6)年。6 例患者(2.3%)在接受这种治疗后尿道内发生了尿路上皮癌(UC)的局部复发。RC 后出现 UC 的局部复发的中位(范围)时间为 2.4(0.7-3.6)年。采用经尿道切除术、新膀胱转为可控性导管引流的尿道切除术以及化疗等多种方法治疗复发。在最后一次随访时,这 6 例患者中有 4 例无病生存,1 例有病生存,1 例死于疾病。
在我们的经验中,涉及尿道的局部复发并不常见。完整的手术切除可以提供良好的结果。对于具有不良临床病理特征的复发,应考虑新辅助化疗。